



NEWS RELEASE

# Savara Announces Participation in Upcoming Investor Healthcare Conferences

2026-02-04

LANGHORNE, Pa.--(BUSINESS WIRE)-- **Savara Inc.** (Nasdaq: **SVRA**) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will host one-on-one meetings and participate in fireside chats at two upcoming investor healthcare conferences.

## Fireside Chats:

### Guggenheim Emerging Outlook: Biotech Summit

February 11<sup>th</sup> at 12:30pm ET

### Oppenheimer 36<sup>th</sup> Annual Healthcare Life Sciences Conference

February 25<sup>th</sup> at 9:20am ET

The live webcasts and subsequent replays will be available on the "**Events & Presentations**" section of the Company's corporate website and will be archived for 90 days.

## About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI\* is a recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary

medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at [www.savarapharma.com](http://www.savarapharma.com) and [LinkedIn](#).

\*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.

**Media and Investor Relations Contact**

Savara Inc.

Temre Johnson, Executive Director, Corporate Affairs

[ir@savarapharma.com](mailto:ir@savarapharma.com)

Source: Savara Inc.